SPD-473 citrate is an active pharmaceutical ingredient (API) used in the pharmaceutical industry for therapeutic applications, particularly in oncology. It targets cancers with KRAS gene mutations, such as lung and colorectal cancers, by inhibiting the function of mutant KRAS proteins, thereby preventing cancer cell growth and spread. Studies also explore its potential in managing inflammatory conditions through immune response modulation and inflammation reduction. It is primarily evaluated in clinical trials to assess efficacy and safety.